What role does stereotactic ablative radiotherapy have in advanced castrate-resistant prostate cancer?

被引：2
|
作者：
Phillips, Ryan [1 ]
Ost, Piet [2 ]
Tran, Phuoc T. [1 ,3 ,4 ]
机构：
[1] Johns Hopkins Univ, Dept Radiat Oncol & Mol Radiat Sci, Baltimore, MD 21218 USA
[2] Univ Ghent, Dept Radiat Oncol & Expt Canc Res, Ghent, Belgium
[3] Johns Hopkins Univ, Dept Oncol, Baltimore, MD 21218 USA
[4] Johns Hopkins Univ, Dept Urol, Baltimore, MD 21218 USA
来源：
FUTURE ONCOLOGY | 2017年 / 13卷 / 24期
关键词：
castration-resistant prostate cancer; neoplasm metastasis; neoplasm recurrence; oligometastasis; prostate cancer; stereotactic ablative radiotherapy; stereotactic body radiation therapy; ANDROGEN DEPRIVATION; BODY RADIOTHERAPY; LUNG-CANCER; THERAPY; HISTORY;
D O I：
10.2217/fon-2017-0337
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：2121 / 2124
页数：4
相关论文
共 50 条
  • [21] Next Generation Sequencing in metastatic castrate-resistant prostate cancer
    Adashek, Jacob J.
    Salgia, Meghan
    Pal, Sumanta K.
    UROLOGY CASE REPORTS, 2018, 19 : 60 - 62
  • [22] Primary treatment of the prostate improves local palliation in men who ultimately develop castrate-resistant prostate cancer
    Won, Andy C. M.
    Gurney, Howard
    Marx, Gavin
    De Souza, Paul
    Patel, Manish I.
    BJU INTERNATIONAL, 2013, 112 (04) : E250 - E255
  • [23] Emerging novel therapies in the treatment of castrate-resistant prostate cancer
    Abdulla, Alym
    Kapoor, Anil
    CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2011, 5 (02): : 120 - 133
  • [24] Exercise for advanced prostate cancer: a multicomponent, feasibility, trial protocol for men with metastatic castrate-resistant prostate cancer (EXACT)
    Brown, Malcolm
    Murphy, Marie
    McDermott, Lauri
    McAneney, Helen
    O'Sullivan, Joe M.
    Jain, Suneil
    Prue, Gillian
    PILOT AND FEASIBILITY STUDIES, 2019, 5 (01)
  • [25] Stereotactic ablative body radiotherapy in patients with prostate cancer
    Loblaw, Andrew
    Liu, Stanley
    Cheung, Patrick
    TRANSLATIONAL ANDROLOGY AND UROLOGY, 2018, 7 (03) : 330 - 340
  • [26] Stereotactic ablative radiotherapy (SABR) for pelvic nodal oligorecurrence in prostate cancer
    Lopez-Valcarcel, Marta
    Valcarcel, Francisco J.
    Velasco, Joaquin
    Zapata, Irma
    Rodriguez, Ruth
    Cardona, Jorge
    Gil, Beatriz
    Cordoba, Sofia
    Benlloch, Raquel
    Hernandez, Maria
    Santana, Sofia
    Gomez, Ricardo
    de la Fuente, Cristina
    Garcia-Berrocal, M. Isabel
    Regueiro, Carlos
    Romero, Jesus
    REPORTS OF PRACTICAL ONCOLOGY AND RADIOTHERAPY, 2024, 29 (04) : 445 - 453
  • [27] Evolving landscape and novel treatments in metastatic castrate-resistant prostate cancer
    Toren, Paul J.
    Gleave, Martin E.
    ASIAN JOURNAL OF ANDROLOGY, 2013, 15 (03) : 342 - 349
  • [28] Somatostatin analogs in the treatment of castrate-resistant prostate cancer: efficacy and tolerability
    Kolesnikov, G. P.
    Semkov, A. S.
    Bystrov, A. A.
    Naumova, I. N.
    ONKOUROLOGIYA, 2016, 12 (03): : 96 - 101
  • [29] Upregulation of MAPK pathway is associated with survival in castrate-resistant prostate cancer
    R Mukherjee
    D H McGuinness
    P McCall
    M A Underwood
    M Seywright
    C Orange
    J Edwards
    British Journal of Cancer, 2011, 104 : 1920 - 1928
  • [30] The evolution and current paradigm of chemotherapy for metastatic castrate-resistant prostate cancer
    Payne, Heather A.
    Aggarwal, Ajay
    Woolf, David K.
    JOURNAL OF CLINICAL UROLOGY, 2011, 4 (01) : S2 - S8
12345